Creeping phase II-ism and the medical pharmaceutical complex: Weapons of mass distraction in the war against lung cancer

Journal of Clinical Oncology

Volumn 23, Issue 22, 2005, Pages 4827-4829

  Turrisi III, Andrew T ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADD ON THERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG RESEARCH; EDITORIAL; ESOPHAGITIS; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT OUTCOME; LUNG TUMOR; METHODOLOGY; NOTE; PHASE 2 CLINICAL TRIAL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II; HUMANS; LUNG NEOPLASMS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 24644482003     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.904     Document Type: Editorial

References (12)

1. Ettinger DS, Berkey BA, Abrams RA, et al: Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: A Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol 23:4991-4998, 2005
2. Ettinger DS, Seiferheld WF, Abrams RA, et al: Cisplatin (P), etoposide (E), paclitaxel (T) and concurrent hyperfractionated thoracic radiotherapy (TRT) for patients (pts) with limited disease (LD) small cell lung cancer (SCLC): Preliminary results of RTOG 96-09. Proc Am Soc Clin Oncol 19:490a, 2000 (abstr 1917)
3. Turrisi AT, Kim K, Blum R, et al: Twice daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999
4. Neill HB, Herndon JE, Miller AD, et al: Randomized phase III trial (CALGB 9732) of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 21:293a, 2002 (abstr 1169)
5. Yokes EE, Herndon JE, Kelley MJ, et al: Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial. J Clin Oncol 22:616, 2004 (suppl, abstr 7005)
6. Belani CP, Natale RB, Lee JS, et al: Randomized phase III trial comparing cisplatin etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCL). Proc Am Soc Clin Oncol 17:455a, 1998 (abstr 1751)
7. Komaki R, Swann S, Ettinger D, et al: Phase I dose escalation study of thoracic irradiation with concurrent chemotherapy for patients with limited small cell lung cancer (LSCLC): Radiation Therapy Oncology Group (RTOG). Int J Radiat Oncol Biol Phys 57:S139, 2003 (suppl 2, abstr 25)
8. Schild SE, Bonner JA, Shanahan TG, et al: Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small cell lung cancer. Int J Radiat Oncol Biol Phys 59:943-951, 2005
9. Gandara DR, Chansky K, Albain KS, et al: Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIb non-small-cell lung cancer: Phase II Southwest Oncology Group study S9504. J Clin Oncol 21:2004-2010, 2003
10. Betticher DC, Schmitz SFH, Tötsch M, et al: Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA non-small-cell lung cancer: A multicenter phase II trial. J Clin Oncol 21:1752-1759, 2003
11. Albain KS, Scott CB, Rusch VR, et al: Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIa (pN-2) non-small-cell lung cancer (NSCLC): Initial results from intergroup trial 0139 (RTOG 9309). Proc Am Soc Clin Oncol 22:621, 2003 (abstr 2497)
12. Turrisi AT, Scott CB, Rusch VR, et al: Randomized trial of chemoradiotherapy to 61 Gy [no S] versus chemoradiotherapy to 45 Gy followed by surgery [S] using cisplatin etoposide in stage IIIa non-small-cell lung cancer (NSCLC): Intergroup trial 0139, RTOG 9309. Int J Radiat Oncol Biol Phys 57:S125, 2003 (suppl 2, abstr 4)